NL-OMON27822已完成不适用
ANTI-CD20 THERAPY FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
niversity Medical Centre UtrechtP.O. Box 855003508 GA Utrecht, The Netherlands0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age > = 18 years
- •2. Chronic GVHD, including skin localization, refractory or dependent to first line treatment consisting of steroids and/or ciclosporine. Refractory cGVHD is defined as progressive cGVHD after at least 2 weeks of first line treatment or no response after 4 weeks of first line treatment.. Dependent cGVHD is defined as an inability to taper immunosuppressive treatment.
排除标准
- •1. Relapse and a life expectancy of < 6 months
- •2. Life expectancy of < 6 months
研究者
相似试验
尚未招募
不适用
Anti-CD20 therapy for the treatment ofchronic graft versus host disease.30 patients with a steroid refractory cGVHD will be treated with anti-B-cell therapyNL-OMON27646Roche Nederland B.V.30
已完成
不适用
Anti-CD20 therapy for the treatment of chronic Graft Versus Host DiseaseChronic Graft Versus Host Disease (cGVHD)Injury, Occupational Diseases, PoisoningFailure and rejection of transplanted organsISRCTN43525354niversity Medical Center Utrecht (UMCU) (The Netherlands)30
已完成
不适用
Anti-CD20 treatment of relapsed or refractory Immune Thrombocytopenic Purpura (ITP) after first line corticosteroid treatment.NL-OMON23430150
已完成
不适用
Anti-CD20 treatment of relapsed or refractory immune thrombocytopaenic purpura (ITP) after first line corticosteroid treatmentImmune thrombocytopaenic purpura (ITP)Haematological DisordersPurpura and other haemorrhagic conditionsISRCTN16619820Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (The Netherlands) - Data Centre150
尚未招募
2 期
Anti-CD20 for the retreatment of primary Sjögren*s syndrome in patients who were included in the placebo-controlled double blinded rituximab study10003816Sjogren's syndromeNL-OMON32498niversitair Medisch Centrum Groningen30